TCM
VRTX icon

TD Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

TD Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.6K Buy
82
+7
+9% +$3.26K ﹤0.01% 285
2025
Q4 		$34K Hold
75
– – ﹤0.01% 281
2025
Q3 		$29.4K Hold
75
– – ﹤0.01% 277
2025
Q2 		$33.4K Buy
75
+73
+3,650% +$33.6K ﹤0.01% 258
2025
Q1 		$970 Hold
2
– – ﹤0.01% 557
2024
Q4 		$805 Buy
+2
New +$927 ﹤0.01% 548

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TD Capital Management's VRTX Position: Q1 2026 in Review

TD Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 9.3% in Q1 2026, buying an estimated $3.26K and bringing the position to 82 shares worth $36.6K. The position accounts for ﹤0.01% of the portfolio, ranked #285.

TD Capital Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • TD Capital Management held 82 shares of Vertex Pharmaceuticals worth $36.6K as of Q1 2026.
  • TD Capital Management bought 7 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.26K.
  • Vertex Pharmaceuticals made up ﹤0.01% of TD Capital Management's portfolio in Q1 2026, its #285 holding.
  • TD Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on TD Capital Management's 13F filing for Q1 2026, filed 11 May 2026.